SEHK:09969

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

Retrieved on: 
星期五, 六月 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLL, Methotrexate, PCNSL, Safety, Neoplasm, Mantle cell lymphoma, Aes, NGS, Intolerance, Lenalidomide, CRR, PR, Prognosis, Indolent, MCL, Cytokine release syndrome, ASCT, Pharmacokinetics, Refractory, PD, PB, Chronic lymphocytic leukemia, CRS, European Hematology Association, Efficacy, Rituximab, HKEX, NHL, Lymphoid leukemia, Relapse, EHA, IGHV, IRC, DLBCL, B-cell lymphoma, PFS

Data of InnoCare's (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

Key Points: 
  • Data of InnoCare's (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
  • At the doses evaluated, ICP-B02 subcutaneously (SC) demonstrated favorable safety profile and promising efficacy in patients with R/R B-cell NHL.
  • Rapid and deep responses, as well as the convenience of SC formulation, support further clinical development for treatment of B cell NHL.
  • Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor (Abstract No.

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

Retrieved on: 
星期二, 六月 11, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, BTK, Patient, IND, TYK2, American Academy, Autoimmune disease, AAD, Investigational New Drug, HKEX, Therapy, Inflammation, Food, JAK, Cancer, Pharmaceutical industry

ICP-332 is a potent and selective TYK2 inhibitor.

Key Points: 
  • ICP-332 is a potent and selective TYK2 inhibitor.
  • ICP-332 showed better efficacy profile across different classes/MoAs of therapies for the treatment of AD patients (not a head-to-head comparison).
  • Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
  • We have developed robust pipeline of differentiated therapeutics for autoimmune disease with significant market potential worldwide, including orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor) and ICP-923 (IL-17 small molecule inhibitor).

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Retrieved on: 
星期四, 五月 16, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, TYK2, Patient, HKEX, Signal transduction, PD, Trial of the century, Safety, Psoriasis, Inflammation, Cancer, Autoimmunity, IL-12, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
  • This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study aimed at evaluating the efficacy, safety, PK and PD characteristics of ICP-488 in Chinese adult patients with moderate to severe plaque psoriasis.
  • ICP-488 has demonstrated good efficacy and safety in the phase I study of treating psoriasis patients.
  • We are very pleased to see the completion of patient enrollment in the phase II clinical trial for the treatment of psoriasis with ICP-488.

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Retrieved on: 
星期五, 三月 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung cancer, EGFR, SRC, NSCLC, Patient, Breakthrough therapy, Trial of the century, DLT, Clinical trial, PACC, HKEX, FDA, SHP2, Food, Pharmaceutical industry

In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.

Key Points: 
  • In July 2023, InnoCare and ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced a clinical development collaboration, accelerating the clinical trial of ICP-189 in combination with furmonertinib in patients with advanced or metastatic NSCLC in China.
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR mutations, including exon 20 insertion mutations.
  • Furmonertinib is also being evaluated for the treatment of NSCLC patients with EGFR P-loop alpha-c helix compressing (PACC) mutations.
  • We will accelerate the clinical study and expect this innovative therapy to benefit more NSCLC patients early.”

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
星期四, 三月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Retrieved on: 
星期三, 三月 13, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SLL, CLL, Hematology, E-3, Incidence, Patient, Malignancy, BCL2, Cancer, Leukemia, Death, IND, Clinical trial, Investigational New Drug, HKEX, BTK, Safety, Marketing, NRDL, Lymphoma, CD19, Pharmaceutical industry

This multicenter, randomized-controlled, open-label clinical study is designed to evaluate the efficacy and safety of ICP-248 combined with orelabrutinib versus immunochemotherapy in treatment-naive patients with CLL/SLL.

Key Points: 
  • This multicenter, randomized-controlled, open-label clinical study is designed to evaluate the efficacy and safety of ICP-248 combined with orelabrutinib versus immunochemotherapy in treatment-naive patients with CLL/SLL.
  • ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
  • BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies.
  • ICP-248 has an anti-tumor effect by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death.

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

Retrieved on: 
星期三, 一月 24, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, TRK, Incidence, Melanoma, Breast cancer, HKEX, Cancer, Lung cancer, Safety, Sun, Clinical trial, Colorectal cancer, Adolescence, NTRK, Trial of the century, Pancreatic cancer, Pharmaceutical industry

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TRKA with resistant mutations G595R or G667C.

Key Points: 
  • Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TRKA with resistant mutations G595R or G667C.
  • InnoCare has been advancing the registrational trial of zurletrectinib in China and is expecting to submit the new drug application in the second half of 2024.
  • Dr. Jasmine, the Co-founder, Chairwoman, and CEO of InnoCare, said, “NTRK gene fusion is a driving factor for various adult and pediatric cancers.
  • It is inspiring that we continue to make positive progress in our clinical research of zurletrectinib for patients of different ages with NTRK gene fusion.

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

Retrieved on: 
星期一, 一月 22, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, ASCT, Patient, Incidence, European Medicines Agency, Tafasitamab, HKEX, EMA, Immunotherapy, Food, DLBCL, FDA, Lenalidomide, BLA, Marketing, National Medical Products Administration, NHL, NMPA, Pharmaceutical industry

Through this program, the first prescription of tafasitamab in combination with lenalidomide was filled today at the Guangdong Clifford Hospital for an eligible DLBCL patient.

Key Points: 
  • Through this program, the first prescription of tafasitamab in combination with lenalidomide was filled today at the Guangdong Clifford Hospital for an eligible DLBCL patient.
  • The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been approved by regulatory authorities for marketing in Hong Kong or Macao.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “We are pleased to provide eligible patients access to tafasitamab in the Greater Bay Area.
  • DLBCL is the most common type of non-Hodgkin lymphoma (NHL), and its incidence accounts for 31% to 34% of NHL globally.

InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

Retrieved on: 
星期二, 一月 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, HKEX, E-3, CD19, BTK, IND, Food, BCL2, Safety, FDA, Investigational New Drug, Pharmacokinetics, Pharmaceutical industry

This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S.

Key Points: 
  • This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S.
  • This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of ICP-248 in hematologic malignancy patients.
  • ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
  • The Phase I dose escalation trial of ICP-248 is ongoing in China, and the preliminary results demonstrated good efficacy and safety profiles.

InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
星期四, 十二月 28, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, HKEX, PST, Conference, Time in China

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development.
  • The J.P. Morgan Healthcare Conference is the most influential event for the global pharma industry and the investment community.
  • The 42nd Conference will be held in San Francisco, the United States, on January 8-11, 2024.
  • January 10, 08:30 AM – 08:55 AM, PST
    (January 11, 00:30 AM – 00:55 AM, Beijing Time)
    During the Conference, we warmly welcome to have in-depth talks with our executives.